Hsbc Holdings PLC Acquires 20,323 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Hsbc Holdings PLC increased its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 5.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 416,381 shares of the medical research company's stock after buying an additional 20,323 shares during the period. Hsbc Holdings PLC owned 0.23% of IQVIA worth $81,856,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of IQV. World Investment Advisors LLC bought a new position in IQVIA in the third quarter worth $14,633,000. Arvest Bank Trust Division purchased a new position in shares of IQVIA during the third quarter valued at approximately $21,079,000. Wilmington Savings Fund Society FSB bought a new stake in shares of IQVIA in the 3rd quarter worth approximately $2,310,000. Tidal Investments LLC grew its stake in shares of IQVIA by 9.3% in the 3rd quarter. Tidal Investments LLC now owns 5,980 shares of the medical research company's stock worth $1,417,000 after buying an additional 509 shares during the last quarter. Finally, Franklin Resources Inc. raised its stake in IQVIA by 1.2% during the third quarter. Franklin Resources Inc. now owns 501,807 shares of the medical research company's stock valued at $117,031,000 after buying an additional 6,011 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on IQV. HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and decreased their target price for the stock from $260.00 to $160.00 in a report on Friday. Truist Financial decreased their price target on IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research note on Thursday, April 10th. Citigroup dropped their price target on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Barclays reaffirmed an "equal weight" rating and issued a $170.00 target price (down previously from $235.00) on shares of IQVIA in a research report on Thursday, April 10th. Finally, BTIG Research downgraded IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Eight analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $237.62.

IQVIA Trading Up 1.7 %

IQV stock traded up $2.51 during mid-day trading on Tuesday, reaching $152.64. 262,814 shares of the stock traded hands, compared to its average volume of 1,419,078. The stock's fifty day moving average is $170.67 and its 200-day moving average is $193.00. The company has a market cap of $26.91 billion, a P/E ratio of 20.33, a P/E/G ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a 52-week low of $135.97 and a 52-week high of $252.88. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.